Cargando…

448. Real World Evaluation of Clinical Outcomes for Short-Duration Remdesivir Therapy in Hospitalized Patients with Mild-Moderate COVID-19

BACKGROUND: The optimal duration of remdesivir for hospitalized patients with COVID-19 remains unclear. National Institute of Health (NIH) Guidelines recommend a standard duration of 5 days or until hospital discharge. This study aims to compare the outcomes of hospitalized patients who received ≤ 4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Williams, Kelsey N, Gauthier, Timothy P, Baker, Stacey W, Cua, Jefferson
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676879/ http://dx.doi.org/10.1093/ofid/ofad500.518

Ejemplares similares

474. Real-World Experience of the Comparative Effectiveness and Safety of Remdesivir and Combination Therapy (Remdesivir and Monoclonal Antibodies) in Immunosuppressed Patients with Mild to Moderate COVID-19: A Retrospective Single-center Study in a Community Setting
por: Hirai, Jun, et al.
Publicado: (2023)

448. COVID-19 Acute Care at Home: A Substitution for Hospitalization in Patients with Mild Symptoms
por: Kammeyer, Joel A, et al.
Publicado: (2021)

448. Can Electronic Clinical Notes Identify Travelers with Zika?
por: Peterson, Kelly, et al.
Publicado: (2018)

518. Comparable Outcomes of Remdesivir and Sotrovimab among High-risk Patients with Mild to Moderate COVID-19 During the Omicron BA.1 Surge
por: Chesdachai, Supavit, et al.
Publicado: (2023)

1083. Long-Term Prognosis of 448 Infectious Endocarditis Followed by an Endocarditis Team
por: Camou, Fabrice, et al.
Publicado: (2018)

Real-World Experience of the Comparative Effectiveness and Safety of Combination Therapy with Remdesivir and Monoclonal Antibodies versus Remdesivir Alone for Patients with Mild-to-Moderate COVID-19 and Immunosuppression: A Retrospective Single-Center Study in Aichi, Japan
por: Hirai, Jun, et al.
Publicado: (2023)

72. Remdesivir vs Standard Care in Patients with Moderate covid-19
por: Marty, Francisco M, et al.
Publicado: (2020)

MED34/448: The Networked Health-Care Environment of the Future: Requirements for new human abilities
por: Patel, V, et al.
Publicado: (1999)

448. Impact of Doxycycline Prophylaxis on Skin and Soft-Tissue Infection Incidence in Naval Special Warfare Trainees
por: Smith, Alfred G, et al.
Publicado: (2019)

561. Safety of Remdesivir vs Standard Care in Patients with Moderate Covid-19
por: Criner, Gerard J, et al.
Publicado: (2020)

Remdesivir Use in the Real-World Setting: An Overview of Available Evidence
por: Akinosoglou, Karolina, et al.
Publicado: (2023)

1589. Real-World Outcomes with Cabotegravir/Rilpivirine: Does Duration of Pre-treatment Viral Suppression Matter?
por: Mesa, Daniel, et al.
Publicado: (2023)

Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19
por: Falcone, Marco, et al.
Publicado: (2022)

557. Impact of Concomitant Hydroxychloroquine Use on Safety and Efficacy of Remdesivir in Moderate COVID-19 Patients
por: Arribas, Jose Ramon, et al.
Publicado: (2020)

448. Disproportionate Burden of COVID-19 on Latinx Residents among Hospitalized Patients at San Francisco’s Public Health Hospital
por: Jain, Vivek, et al.
Publicado: (2020)

Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
por: Joshi, Shashank, et al.
Publicado: (2022)

PM448. Investigation of maternal effects, maternal-fetal interactions and parent-of-origin effects (imprinting), using mothers and their offspring with schizophrenia
por: Lee, Byung Dae, et al.
Publicado: (2016)

Remdesivir: Remedy the world is waiting for?
por: Suranagi, Umesh Devappa, et al.
Publicado: (2020)

Real-world outcomes of COVID-19 treatment with remdesivir in a Spanish hospital
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2021)

Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
por: Kim, Taeyun, et al.
Publicado: (2022)

Duration of Reproductive Period and Risk of Transitioning to Mild Cognitive Impairment and Dementia
por: Yoneda, Tomiko, et al.
Publicado: (2021)

Duration of Reproductive Period and Risk of Transitioning to Mild Cognitive Impairment and Dementia
por: Knight, Jamie, et al.
Publicado: (2021)

Neuroanatomical Moderators of the Impact of Mild Behavioral Impairment on Cognition
por: Rouse, Hillary, et al.
Publicado: (2021)

PIN82 Real-World Utilization of Remdesivir in 2020: A Retrospective Cohort Study
por: Mozaffari, E., et al.
Publicado: (2021)

Sonata in D major K. 448 Andante mit Variationen K. 501 /
por: Mozart, Wolfgang Amadeus, 1756-1791
Publicado: (1993)

538. Clinical Evaluation of Drug-drug Interactions with Remdesivir
por: Peng, Chi-Chi, et al.
Publicado: (2023)

Evaluation of Remdesivir for Mildly to Moderately Ill Patients with COVID-19: A Single-Arm, Single-Center, Retrospective Study
por: Miyazaki, Motoyasu, et al.
Publicado: (2022)

Prediction of the Rehabilitation Duration and Risk Management for Mild-Moderate COVID-19
por: Zheng, Qiong-Na, et al.
Publicado: (2020)

Remdesivir treatment for patients with moderate to severe COVID-19
por: HASANOĞLU, İmran, et al.
Publicado: (2022)

Unmet Needs and Behavioral Expressions: The Perspective of Individuals with Mild to Moderate Dementia
por: Minyo, Morgan, et al.
Publicado: (2020)

Moderators of Dual Task Gait Effects in Mild Cognitive Impairment and Dementia
por: Ofori, Edward, et al.
Publicado: (2021)

550. Effectiveness of Remdesivir for Treatment of COVID-19 in the Outpatient Setting
por: Vo, Vinny P, et al.
Publicado: (2023)

A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis
por: Mehta, Ravindra M., et al.
Publicado: (2021)

Comparison of Short-Course and Conventional Antimicrobial Duration in Mild and Moderate Complicated Intra-Abdominal Infections: A randomised controlled trial
por: Vinodhini, P., et al.
Publicado: (2023)

SAT-448 Pituitary Tumors in the Eldery: An Important and Underdiagnosed Condition
por: Rosa, Isabella, et al.
Publicado: (2019)

Musical components important for the Mozart K448 effect in epilepsy
por: Quon, Robert J., et al.
Publicado: (2021)

The antitumor effect of miR-448 in epithelial ovarian cancer
por: Li, Tao, et al.
Publicado: (2020)

ODP448 A Case of Lithium-Induced Silent Thyroiditis
por: Dawahir, Wafa, et al.
Publicado: (2022)

Correction to Lancet Gastroenterol Hepatol 2021; 6: 448–58
Publicado: (2022)

1127. Effectiveness of Remdesivir as Treatment for COVID-19 Positive US Veterans
por: Jeyapalina, Sujee, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ui8q4724lj755kdc3vs3uacqko